Press
Drug discovery & bio
Coverage of AI-driven drug discovery and biotech collaboration.
In brief
Reports on the Open Discovery Challenge, antimicrobial-peptide prediction validated by academia, and cell-based experimental validation partnerships.
Government programmes & public sectorGlobal benchmark recordsModels & architectureInference acceleration & servingOn-device & compressionDrug discovery & bioBusiness & partnershipsAll coverage
Drug discovery & bio coverage
- 2026-08-23Vizen MedicalVizen Medical analysis — what the early Claude 43.7 figure from the Open Discovery Challenge does and does not show
- 2026-08-22RuntimeWire (Global)FINAL-Bench finds a 0.21 AUROC gap between time and random splits
- 2026-08-19AP News (USA)Press release on AP News — OpenAI, Claude, Gemini or DeepSeek: which AI is better at discovering drug candidates?
- 2026-08-18AI TimesVIDRAFT opens its AI drug-discovery project — over 2,000 candidate compounds submitted in three days
- 2026-08-18Electronic TimesClaude-family models lead a real drug-candidate competition for malaria and tuberculosis
- 2026-07-08IT ChosunVIDRAFT's model merging technology 'Darwin' highlighted by Chinese tech media
- 2026-02-26ANVI (Israel)Israeli AI outlet ANVI in-depth analysis of FINAL-Bench — "Can AI correct its own errors?" (AGI self-correction bottleneck)
- 2025-06-05BrunchA 'lie detector' for medical AI has appeared!
Note
Each entry links to the original article on the publisher's own site. Copyright of the article text belongs to each publisher.